CLINICAL TRIALS PROFILE FOR TOREMIFENE CITRATE
✉ Email this page to a colleague
All Clinical Trials for toremifene citrate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00106691 ↗ | Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) | Completed | GTx | Phase 3 | 2005-01-01 | The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN). |
| NCT00129142 ↗ | Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy | Completed | GTx | Phase 3 | 2003-10-01 | Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural hormone called testosterone. This type of therapy is very effective for the treatment of prostate cancer. However, one of the side effects is bone loss or thinning of the bones that can lead to osteoporosis and an increased risk of bone fractures (breaking of the bones). The purpose of the study is to determine whether or not the addition of toremifene citrate (the study drug) to therapy can prevent or decrease the number of bone fractures and to evaluate its impact on side effects associated with testosterone reduction therapy. |
| NCT00437359 ↗ | Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer | Terminated | Japan Breast Cancer Research Network | Phase 2 | 2007-05-01 | To investigate the benefit of postoperative adjuvant therapy using sequential administration of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast cancer. |
| NCT01214291 ↗ | Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer | Withdrawn | Ipsen | Phase 3 | 2011-03-01 | The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy. |
| NCT01214291 ↗ | Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer | Withdrawn | GTx | Phase 3 | 2011-03-01 | The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy. |
| NCT02017197 ↗ | Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2014-08-01 | The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for toremifene citrate
Condition Name
Clinical Trial Locations for toremifene citrate
Trials by Country
Clinical Trial Progress for toremifene citrate
Clinical Trial Phase
Clinical Trial Sponsors for toremifene citrate
Sponsor Name
